Proglucagon: difference between revisions
Diff·revision 22 → 23·08:49, 12 Jun 2025
Difference between revision 22 and revision 23 of Proglucagon. 3 lines changed; the page grew by 401 bytes.
| Revision 22 — 11:53, 18 May 2025 HalfLifeHavel (talk) the half-life given was for the intact peptide; label it 5,743 bytes ±0 | Revision 23 — 08:49, 12 Jun 2025 ArcuateArt (talk) add short description 6,144 bytes +401 | ||
|---|---|---|---|
| 42 | Sandwich assays using two antibodies against opposite ends of the mature glucagon sequence, and [[Liquid chromatography-mass spectrometry|LC-MS]] methods, have improved the position substantially.{{r|wewer2014}} Any comparison of glucagon data across studies should establish which assay was used before the numbers are treated as commensurable — this is a frequent source of apparent contradiction in the incretin literature.{{r|campbell2013}} | 42 | Sandwich assays using two antibodies against opposite ends of the mature glucagon sequence, and [[Liquid chromatography-mass spectrometry|LC-MS]] methods, have improved the position substantially.{{r|wewer2014}} Any comparison of glucagon data across studies should establish which assay was used before the numbers are treated as commensurable — this is a frequent source of apparent contradiction in the incretin literature.{{r|campbell2013}} |
| 43 | 43 | ||
| + | 44 | == Therapeutic exploitation of the family == | |
| + | 45 | Because glucagon, GLP-1 and GIP receptors share a common ancestry and their ligands share a common precursor or fold, peptides can be engineered to engage more than one. Tirzepatide engages GIP and GLP-1 receptors; [[Retatrutide|retatrutide]] adds the glucagon receptor; [[Survodutide|survodutide]] engages glucagon and GLP-1 receptors.{{r|campbell2013}} | |
| + | 46 | ||
| 44 | == References == | 47 | == References == |
| 45 | {{reflist}} | 48 | {{reflist}} |